Subscribe
shutterstock-12540832
Eric Gevaert / Shutterstock.com
30 May 2014AmericasNabeela Rasheed

Dolly the sheep: the demise of biotechnology patents

The US Federal Circuit has recently been called upon to apply the Prometheus and Myriad decisions to a particularly famous project: the creation of Dolly the cloned sheep.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Federal Circuit refuses to review Dolly the sheep ruling
14 August 2014   The US Court of Appeals for the Federal Circuit has refused to grant an en banc review of its ruling that cloned animals made by methods that produced Dolly the sheep cannot be patented, according to Law360.
Americas
Bioverativ and Bicycle Therapeutics in $10m haemophilia deal
7 September 2017   Biotechnology companies Bioverativ and Bicycle Therapeutics have entered into an agreement to develop and commercialise therapies for haemophilia and sickle cell disease.


Editor's picks

Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024

Editor's picks

Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024
Americas
Litigation implications of the USPTO’s terminal disclaimer proposal
29 August 2024
Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024
Europe
Labour govt appoints new Minister with IP oversight
9 July 2024
Americas
New-look WIPR Leaders 2024 is ‘most rigorous’ yet
2 July 2024
Americas
Earthquake Chevron: A massive shock to the system?
2 July 2024

More on this story

Americas
Federal Circuit refuses to review Dolly the sheep ruling
14 August 2014   The US Court of Appeals for the Federal Circuit has refused to grant an en banc review of its ruling that cloned animals made by methods that produced Dolly the sheep cannot be patented, according to Law360.
Americas
Bioverativ and Bicycle Therapeutics in $10m haemophilia deal
7 September 2017   Biotechnology companies Bioverativ and Bicycle Therapeutics have entered into an agreement to develop and commercialise therapies for haemophilia and sickle cell disease.

More on this story

Americas
Federal Circuit refuses to review Dolly the sheep ruling
14 August 2014   The US Court of Appeals for the Federal Circuit has refused to grant an en banc review of its ruling that cloned animals made by methods that produced Dolly the sheep cannot be patented, according to Law360.
Americas
Bioverativ and Bicycle Therapeutics in $10m haemophilia deal
7 September 2017   Biotechnology companies Bioverativ and Bicycle Therapeutics have entered into an agreement to develop and commercialise therapies for haemophilia and sickle cell disease.

More features

Gilead scores win in fake HIV drug dispute
Polsinelli grows roster with ex-corporate counsel
Sandoz wins $137.2m payout for lost profits in generic launch
Dexcom suffers second patent revocation at hands of UPC
Sanofi signs global rights deal to develop rare cancer therapy
WBD to merge with firm to create ‘powerhouse’ practice
Novo Nordisk files fresh lawsuits to intercept Wegovy generics
AstraZeneca unit draws line under Samsung dispute